Effects of benztropine on ketamine-induced behaviors in Cebus monkeys

Behavioural Pharmacology

Volumn 12, Issue 4, 2001, Pages 293-298

  Shiigi, Y ^a   Casey, Daniel E ^b,c,d  

^a Welfide Corporation   (Japan)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Anticholinergics; Behavior; Benztropine; Cebus monkey; Ketamine; NMDA; Nonhuman primates

Indexed keywords

BENZATROPINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DYSTONIA; FEMALE; HYPERSALIVATION; LOCOMOTION; MALE; NONHUMAN; PERCEPTION; PRIMATE; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 0034907726     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200107000-00008     Document Type: Article

References (35)

1. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-D-aspartate
2. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
3. Radioreceptor binding profile of the atypical antipsychotic olanzapine
4. Motor and mental aspects of extrapyramidal syndromes
5. Dopamine, acetylcholine, and GABA effects in acute dystonia in primates
6. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
7. Abnormal mental states induced by phencyclidine as a model of schizophrenia
8. A multiple comparison procedure for comparing several treatments with a control
9. The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease
10. The use of ranks to avoid the assumption of normality implicit in the analysis of variance
11. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
12. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: A prospective, double-blind trial
13. Direct regulation of acetylcholine release by N-methyl-D-aspartic acid receptors in rat striatum
14. Recent advances in the phencyclidine model of schizophrenia
15. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine
16. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes
17. Low cerebrospinal fluid glutamate in schizophrenia patients and a new hypothesis on schizophrenia
18. Modulation of striatal acetylcholine concentrations by NMDA and the competitive NMDA receptor-antagonist AP-5: An in vivo microdialysis study
19. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
20. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
21. Problems with ketamine anaesthesia
22. MK-801-induced dystonia in cebus monkeys
23. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
24. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
25. Effects of cholinergic and anticholinergic drugs on ketamine-induced linguopharyngeal motor activity
26. Spontaneous and drug-induced movement disorders in psychotic patients
27. An overview of the mechanism of action of clozapine
28. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis
29. Glutamate receptor dysfunction and schizophrenia
30. NMDA antagonist neurotoxicity: Mechanism and prevention
31. Acute dystonia induced by neuroleptic drugs
32. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: A possible animal model of schizophrenia
33. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates
34. Treatment of negative schizophrenic symptoms with trihexyphenidyl
35. Ketamine decreases the open time of single-channel currents activated by acetylcholine